ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Journal and News Scan
May 19, 2022
Submitted by: Mary Hammon
A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a discrepancy in data. This has rekindled concerns about reliance on the landmark trial data in the newest coronary revascularization guidelines. CTSNet recently recently published a webinar on this topic featuring leading CT surgeons around the globe.
May 18, 2022
Submitted by: Aristotle Protopapas
Gripping vignette of a fatal case of renocardiac pathologies. The stills from the (sadly non-contrast) CTA are most interesting.
May 10, 2022
Submitted by: Saurabh Gupta
Meta-analysis of 119 studies (approx 38,000 patients) evaluating outcomes of minimally invasive mitral valve surgery with conventional sternotomy approach.
MMVS was associated with fewer days in hospital (RCT: MD: -2.2 days, 95% CI, [-3.7 to -0.8]; observational: MD: -2.4 days, 95% CI, [-2.7 to -2.1]). Observational studies suggested that MMVS reduced transfusion requirements with fewer units transfused per patient (MD: -1.2; 95% CI, [-1.6 to -0.9]) and fewer patients transfused (RR, 0.7; 95% CI, [0.6-0.7]). Observational data also suggested lower mortality with MMVS (RR, 0.6; 95% CI, [0.5-0.7], p < .001, I2 = 0%), but this was not corroborated by RCT data. The risk of postoperative mitral regurgitation (≥2+ or requiring re-intervention) did not differ between the two groups.
May 10, 2022
Submitted by: Saurabh Gupta
Data from Scientific Registry of Transplant Recipients was modeled over 30 years to evaluate temporal trends, as well as graft survival.
Among 56,488 primary adult heart recipients, we observed 5529 (9.8%) all-cause deaths and 1933 (3.4%) graft failure events within 6 months posttransplant. Prevalence of known recipient risk factors increased over time. Unadjusted modeling demonstrated a significant 30-year improvement in graft survival, averaging 2.6% per year (95% confidence interval, 2.4-2.9; P for trend < .001). After adjusting for population changes the 30-year trend remained significant and graft survival improved on average 3.0% per year (95% confidence interval, 2.6-3.3). Regression modeling identified multiple predictors of graft survival. Modeling 2 additional outcomes of 6-month mortality and 6-month graft failure produced similar results.
May 10, 2022
Submitted by: Saurabh Gupta
Retrospective review (propensity-matched) comparing patients undergoing PCI vs minimally invasive CABG for complex LAD lesions.
Overall 9-year survival was not significantly different between patient groups both before and after propensity matching. Midterm mortality in the matched minimally invasive direct coronary artery bypass group was low, irrespective of patient risk profile. By contrast, advanced age (hazard ratio, 1.10; P = .012) and obesity (hazard ratio, 1.09; P = .044) predicted increased late death after drug-eluting stent percutaneous coronary intervention among matched patients. Patients who underwent minimally invasive direct coronary artery bypass were significantly less likely to require repeat left anterior descending revascularization than those who had percutaneous coronary intervention, both before and after propensity matching. Smaller stent diameter in drug-eluting stent percutaneous coronary intervention was associated with increased left anterior descending reintervention (hazard ratio, 3.53; P = .005).
May 6, 2022
Submitted by: Mary Hammon
A new “aspirational” document delivers some goals for multidisciplinary discussions, but its relevance on the global stage is unclear.
May 6, 2022
Submitted by: Christopher Anderson
Recommendations for intraoperative lymph node evaluation are uniform regardless of whether a primary tumor is clinical T1a or T2a according to TNM 8th edition for stage I non-small cell lung cancer (NSCLC). We quantified nodal disease risk in patients with T1a disease (≤1 cm).
May 3, 2022
Submitted by: Emily Farkas
Lack of prioritization of simulation activities is commonly reported by trainees for a variety of reasons, including time constraints and perceived translational benefit. These barriers become even more pronounced in low-income countries with limited healthcare resources, as the current era of simulation-based training often requires substantial investments of time, money, and teaching personnel [4,5].
A low-fidelity compact simulator with all necessary instruments and materials contained within a 12.5-inch toolbox was utilized by thirty general surgery residents from an academic medical center with instruction on how to perform two different vascular anastomoses. Participants were then sent an anonymized survey evaluating its practicality and helpfulness.
Further, as a global health equity initiative, current efforts include implementing a “make one locally, give one globally” approach, whereby training programs can assist in creating additional simulators and distributing them to partner surgical training programs in low- and middle-income countries.
April 29, 2022
Submitted by: Christopher Anderson
Extracorporeal membrane oxygenation (ECMO) can be effective for refractory acute respiratory distress syndrome (ARDS) in patients with influenza, but its utility in patients with coronavirus disease 2019 (COVID-19) is uncertain. We compared outcomes of patients with refractory ARDS from COVID-19 and influenza placed on ECMO.
Propensity Score Matched Analysis of Cleft Closure in Complete Atrioventricular Septal Defect Repair
April 29, 2022
Submitted by: Christopher Anderson
Repair of complete atrioventricular septal defect (cAVSD) is achieved with low mortality. However, there is a high rate of reoperation on the left atrioventricular valve (LAVV), which is often attributed to nonclosure of the cleft. Although nonclosure of the cleft has been reported to be a risk factor for reoperation, no randomized controlled or propensity-matched trials have ever been performed. We investigated the effect of cleft closure on outcomes after cAVSD repair.